Business Wire

Eight Sleep Continues Expansion Into Europe With Pod Pro Cover Now Available for Purchase in Belgium, France, Germany, Italy, Netherlands and Spain

Share

Eight Sleep, the world's first sleep fitness company, today announced that customers based in Belgium, France, Germany, Italy, Netherlands and Spain can now purchase the brand’s best-selling Pod Pro Cover, exclusively at eightsleep.com. Available sizes will be EU Double, EU Large Double and EU Super King. The Pod Pro Cover uses PerfectFitTM design to fit any mattress of up to 40cm (16 inches) in height so users can enjoy Eight Sleep’s proprietary sleep improving technology while continuing to use their current mattress. Today’s announcement immediately follows Eight Sleep’s expansion to the UK which began last month, delivering on the company’s plan to extend distribution to international markets following their Series C round of $86M.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117005295/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Eight Sleep Continues Expansion into Europe with Pod Pro Cover Now Available for Purchase in Belgium, France, Germany, Italy, Netherlands and Spain (Photo: Business Wire)

The Pod Pro Cover helps people sleep better and ultimately, live better, longer, happier lives by leveraging innovative technology to create a personalized microclimate in bed. Using health-grade sensors and creating individual AI models, the Pod Pro Cover adapts the sleeping temperature by responding to each user’s sleep patterns, temperature preferences, environment values, and feedback history. This data-driven approach guides the user towards sleep optimization, and case studies have shown that Eight Sleep products help users to fall asleep up to 40% faster, get up to 20% more deep sleep, experience 30% fewer mid-night wake ups, and up to 30% fewer tosses and turns.

Currently more than 100 pro athletes rely on the Eight Sleep Pod technology to power their recovery, including current and former Olympians Matthew Dellavedova (2020 Bronze Medalist, Basketball), Daryl Homer (2020, and 2016 Silver Medalist, Fencing), Jane Campbell (2020 Bronze Medalist, Soccer), Apolo Ohno (Two-Time Gold Medalist, Speed Skating), Justin Medeiros (2021 Crossfit Games and 2021 Rogue Invitational Winner) and Daniel Sturridge (English Soccer Player).

The Pod Pro Cover is available for purchase and delivery in select Europe countries as of today with prices starting at $1,695 USD. At checkout, prices are reflected in USD, but EU-based customers will be charged in local currency based on the exchange rate at that moment. There are no additional costs for shipping, duties or returns. Eight Sleep maintains its 30-day free returns policy, as well as a 2-year limited warranty for any Pod Pro Cover purchased directly from the company.

“Our recent expansion to the UK was just the start of scaling our business globally and we’re excited to announce six more countries in Europe that now have access to our advanced tech-based products improving overall health,” said Matteo Franceschetti, Co-founder and CEO of Eight Sleep. “With the goal of becoming accessible to all people, continued growth is a focal point right now. We are helping people everywhere achieve optimal health and that requires availability. This an exciting step for more users throughout Europe to join existing customers as devoted fans of Eight Sleep products.”

Eight Sleep: Creating the Sleep Fitness Movement

Eight Sleep has revolutionized the archaic sleep category by leading the way in the sleep fitness movement. Eight Sleep recently announced an exclusive collaboration with leading global fitness brand Barry’s to become its Official Sleep Fitness Partner. The active Barry’s community can now level up their health and wellness, not only through fitness, but also through Eight Sleep’s advanced sleep technology. This partnership brings both communities greater access and education to the latest technologies and fitness regimes to elevate their health. With another main focus on R&D, Eight Sleep recently launched SleepOS, the world’s first operating system for sleep optimization that includes a new suite of cutting-edge features: Smart Temp Autopilot and Sleep and Health Insights. SleepOS acts as the brains of Eight Sleep and uses data to personalize and adjust the Pod towards each users’ unique sleep fitness goals. These features receive software updates regularly, continuously improving the experience of Eight Sleep products.

About Eight Sleep

Eight Sleep is the world's first sleep fitness company with a mission to fuel human potential through optimal sleep. Founded in 2014, Eight Sleep leverages thermoregulation, data, and technology to restore individuals to their peak energy levels every morning. Eight Sleep was named one of Fast Company's "Most Innovative Companies of 2018" and recognized two years in a row by TIME's Best Inventions of the Year. To learn more, visit eightsleep.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Jack Taylor PR
Nadine Hachicho
nadine@jacktaylorpr.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ReNAgade Therapeutics Continues Commitment to GanNA Bio and Glycan Biology27.4.2024 02:09:00 CEST | Press release

ReNAgade Therapeutics, a company unlocking the limitless potential for RNA medicines,today announced its ongoing commitment to exploring the therapeutic opportunity of glycobiology through support for ongoing research at GanNA Bio, and the integration of key individuals of GanNA Bio into the ReNAgade ecosystem. GanNA founders Carolyn Bertozzi, Ph.D., and Richard D. Cummings, Ph.D, will now serve as advisors to ReNAgade. “ReNAgade will continue to benefit tremendously from GanNA’s promising work in developing extra-hepatic delivery technology that helps expand the breadth and potential of our own RNA medicines,” said Brian Goodman, Co-founder of ReNAgade. “Delivery is foundational to ReNAgade’s mission to overcome the current limitations of RNA medicines. We believe the technology developed within GanNA will help further solidify ReNAgade’s leadership position as we continue advancing our unique, integrated therapeutic platform.” Formed in 2021 and invested in by ReNAgade, GanNA Bio har

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

HiddenA line styled icon from Orion Icon Library.Eye